Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Trypsinogen 1
1. Trypsinogen From Bovine Pancreas
2. 9002-08-8
3. Einecs 232-651-3
4. (2s,5s,8s,11s,14s)-2-(4-aminobutyl)-14-((s)-2-((s)-1-((s)-2-aminopropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5,8,11-tris(carboxymethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecane-1,16-dioic Acid
Molecular Weight | 921.9 g/mol |
---|---|
Molecular Formula | C39H55N9O17 |
XLogP3 | -8.9 |
Hydrogen Bond Donor Count | 13 |
Hydrogen Bond Acceptor Count | 19 |
Rotatable Bond Count | 28 |
Exact Mass | 921.37159132 g/mol |
Monoisotopic Mass | 921.37159132 g/mol |
Topological Polar Surface Area | 433 Ų |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 1770 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Trypsinogen,Chymotrypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Trypsinogen,Chymotrypsinogen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 15, 2023
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatm...
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2022
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First...
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 12, 2022
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma’s CEO Comments On The 39 Granted Patents and 26 Patent Applications Under Exam...
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 05, 2022
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work ...
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2022
Details:
PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Appro...
Details : PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 26, 2022
Details:
PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
Details : PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 18, 2022
Details:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in advanced cancer patients suffering from solid tumors.
Lead Product(s): Chymotrypsinogen,Trypsinogen
Therapeutic Area: Oncology Brand Name: PRP
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in advanced cancer patients suffering from solid tumors.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 02, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?